(Q84500351)
Statements
Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients (English)
Mads Nybo
Simone Rørdam Preil
Henning Friis Juhl
Malene Olesen
scientific article published on 29 July 2011